

# Jason D Wright

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/665371/publications.pdf>

Version: 2024-02-01

492  
papers

17,472  
citations

15001

68  
h-index

31191

106  
g-index

494  
all docs

494  
docs citations

494  
times ranked

17438  
citing authors

#	ARTICLE	IF	CITATIONS
1	Postthrombotic Syndrome and Chronic Pulmonary Embolism after Obstetric Venous Thromboembolism. <i>American Journal of Perinatology</i> , 2023, 40, 022-024.	0.6	1
2	Utilization of sentinel lymph node biopsy in the early ovarian cancer surgery. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 525-532.	0.8	5
3	Decision to Incision and Risk for Fetal Acidemia, Low Apgar Scores, and Hypoxic Ischemic Encephalopathy. <i>American Journal of Perinatology</i> , 2022, 39, 416-424.	0.6	3
4	Risk for and temporal trends in cesarean surgical complications. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 6489-6497.	0.7	1
5	Longitudinal Risk Adjustment for Maternal End-Organ Injury and Death. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 6346-6352.	0.7	1
6	17-alpha hydroxyprogesterone caproate and risk for venous thromboembolism during pregnancy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 6336-6337.	0.7	1
7	Maternal morbidity and mortality associated with epilepsy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 7917-7923.	0.7	2
8	Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma. <i>Journal of Minimally Invasive Gynecology</i> , 2022, 29, 119-127.	0.3	4
9	Association between hysterectomy wait-time and all-cause mortality for micro-invasive cervical cancer: treatment implications during the coronavirus pandemic. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 283-287.	0.8	3
10	Trends in and complications associated with mental health condition diagnoses during delivery hospitalizations. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 405.e1-405.e16.	0.7	15
11	Comparison of Perioperative Outcomes in Heart Failure Patients With Reduced Versus Preserved Ejection Fraction After Noncardiac Surgery. <i>Annals of Surgery</i> , 2022, 275, 807-815.	2.1	7
12	Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States. <i>Gynecologic Oncology</i> , 2022, 164, 46-52.	0.6	12
13	Hospital surgical volume outcome relationship in caesarean hysterectomy for placenta accreta spectrum. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 986-993.	1.1	4
14	Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. <i>JAMA Oncology</i> , 2022, 8, 159.	3.4	5
15	Adverse Outcomes during Postpartum Readmissions after Deliveries Complicated by Hypertensive Disorders of Pregnancy. <i>American Journal of Perinatology</i> , 2022, 39, 699-706.	0.6	5
16	Out-of-network bills among privately insured patients undergoing hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 543.e1-543.e45.	0.7	1
17	Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 1647-1654.	0.8	1
18	Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States. <i>Gynecologic Oncology</i> , 2022, 164, 651-657.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Validation of the 2011 FIGO staging schema for advanced vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 474-479.	1.2	5
20	Authors' reply re: Covariate analysis query: Hospital surgical volumeâ€œoutcome relationship in caesarean hysterectomy for placenta accreta spectrum. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, , .	1.1	0
21	Uptake and outcomes of sentinel lymph node mapping in women undergoing minimally invasive surgery for endometrial cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1591-1599.	1.1	4
22	COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic. <i>Gynecologic Oncology</i> , 2022, 164, 304-310.	0.6	8
23	Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. <i>Gynecologic Oncology</i> , 2022, 164, 341-347.	0.6	1
24	Nationwide Estimates of Annual Inpatient and Outpatient Hysterectomies Performed in the United States. <i>Obstetrics and Gynecology</i> , 2022, 139, 446-448.	1.2	21
25	Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer. <i>Gynecologic Oncology</i> , 2022, 165, 264-269.	0.6	4
26	Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
27	Incorporation of sentinel lymph node biopsy in cervical cancer surgery: Recent U.S. trends. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1407-1413.	0.5	6
28	Safety Warning about Laparoscopic Power Morcellation in Hysterectomy: A Cost-Effectiveness Analysis of National Impact. <i>Women S Health Reports</i> , 2022, 3, 369-384.	0.4	1
29	Population incidence and characteristics of secondary breast cancer after uterine cancer: a competing risk analysis. <i>Archives of Gynecology and Obstetrics</i> , 2022, , 1.	0.8	0
30	Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer. <i>Gynecologic Oncology</i> , 2022, 165, 160-168.	0.6	2
31	Trends in human papillomavirus vaccination among women aged 27 to 45 years, from 2017 to 2019. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 568-570.e1.	0.7	0
32	Association between hospital treatment volume and major complications in ovarian hyperstimulation syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 272, 240-246.	0.5	0
33	Cancer-Specific Mortality in Asian American Women Diagnosed with Gynecologic Cancer: A Nationwide Population-Based Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 578-587.	1.1	4
34	The Effect of a Web-Based Cervical Cancer Survivorâ€™s Story on Parents' Behavior and Willingness to Consider Human Papillomavirus Vaccination for Daughters: Randomized Controlled Trial. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e34715.	1.2	5
35	Racial and ethnic differences in the adoption of opportunistic salpingectomy for ovarian cancer prevention in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 257.e1-257.e22.	0.7	4
36	Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.. <i>Gynecologic Oncology</i> , 2022, , .	0.6	3

#	ARTICLE	IF	CITATIONS
37	Adjuvant and first line chemotherapy use for endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2022, 41, 101002.	0.3	2
38	Utilization and Outcomes of Sentinel Lymph Node Biopsy for Early Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2022, 139, 809-820.	1.2	14
39	New persistent opioid use among adolescents and young adults with sarcoma. <i>Cancer</i> , 2022, 128, 2777-2785.	2.0	6
40	Assessment of Severe Maternal Morbidity and Mortality in Pregnancies Complicated by Cancer in the US. <i>JAMA Oncology</i> , 2022, 8, 1213.	3.4	18
41	Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer. <i>Gynecologic Oncology</i> , 2022, , .	0.6	3
42	Obstetric outcomes among women with a liver transplant. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 2932-2937.	0.7	5
43	Patterns of care for women with placenta accreta spectrum. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 3370-3376.	0.7	7
44	Postpartum hemorrhage and risk for postpartum readmission. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 187-194.	0.7	19
45	Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. <i>Gynecologic Oncology</i> , 2021, 160, 438-444.	0.6	9
46	The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 537-543.	0.3	13
47	Less radical surgery for early-stage cervical cancer: a systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 348-358.e5.	0.7	19
48	Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 319-321.	0.7	12
49	Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy. <i>Cancer</i> , 2021, 127, 1057-1067.	2.0	7
50	Cost of care for the initial management of cervical cancer in women with commercial insurance. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 286.e1-286.e11.	0.7	9
51	National trends and outcomes of morbidly obese women who underwent inpatient hysterectomy for benign gynecological disease in the USA. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 459-470.	1.3	11
52	Postpartum Psychiatric Admissions in the United States. <i>American Journal of Perinatology</i> , 2021, 38, 115-121.	0.6	4
53	Surveillance in Older Women With Incidental Ovarian Cysts: Maximal Projected Benefits by Age and Comorbidity Level. <i>Journal of the American College of Radiology</i> , 2021, 18, 10-18.	0.9	3
54	Quantitative analysis of abnormalities in gynecologic cytopathology with deep learning. <i>Laboratory Investigation</i> , 2021, 101, 513-524.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Receipt of anticoagulation after venous thromboembolism diagnoses during delivery hospitalizations. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, , 1-3.	0.7	1
56	Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal Cytology. <i>Annals of Surgical Oncology</i> , 2021, 28, 7591-7603.	0.7	10
57	Trends in Use of Myomectomy for the Surgical Management of Uterine Leiomyomas in Perimenopausal and Postmenopausal Women. <i>Obstetrics and Gynecology</i> , 2021, 137, 843-845.	1.2	2
58	Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. <i>Gynecologic Oncology</i> , 2021, 161, 39-45.	0.6	13
59	Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014. <i>JAMA Network Open</i> , 2021, 4, e218373.	2.8	15
60	Uptake and Outcomes of Sentinel Lymph Node Mapping in Women With Atypical Endometrial Hyperplasia. <i>Obstetrics and Gynecology</i> , 2021, 137, 924-934.	1.2	18
61	Racial and Ethnic Disparities in Peripartum Hysterectomy Risk and Outcomes. <i>American Journal of Perinatology</i> , 2021, 38, 999-1009.	0.6	7
62	The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial cancer surgery. <i>Gynecologic Oncology</i> , 2021, 161, 353-360.	0.6	9
63	Minimal risk for minimally invasive hysterectomy for stage IA cervical cancer?. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1104-1105.	1.2	2
64	Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. <i>Gynecologic Oncology</i> , 2021, 161, 414-421.	0.6	4
65	Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	1
66	Use of fertility preservation services in male reproductive-aged cancer patients. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100716.	0.3	6
67	Hospital variation in responses to safety warnings about power morcellation in hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 589.e1-589.e13.	0.7	3
68	Ovarian conservation for young women with early-stage, low-grade endometrial cancer: a 2-step schema. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 574-584.	0.7	30
69	Services and payer mix of Black-serving hospitals and related severe maternal morbidity. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 605.e1-605.e13.	0.7	4
70	Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma. <i>Gynecologic Oncology</i> , 2021, 161, 734-740.	0.6	2
71	Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 399.e1-399.e32.	0.7	24
72	Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States. <i>Gynecologic Oncology</i> , 2021, 161, 710-719.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. <i>Gynecologic Oncology</i> , 2021, 162, 56-64.	0.6	9
74	Disparities in Access to High-Volume Surgeons Within High-Volume Hospitals for Hysterectomy. <i>Obstetrics and Gynecology</i> , 2021, 138, 208-217.	1.2	18
75	Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States. <i>Gynecologic Oncology</i> , 2021, 162, 43-49.	0.6	20
76	Intraoperative Rupture of the Ovarian Capsule in Early-Stage Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2021, 138, 261-271.	1.2	7
77	Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance. <i>Gynecologic Oncology</i> , 2021, 162, 18-23.	0.6	6
78	Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. <i>JCO Oncology Practice</i> , 2021, 17, e1215-e1224.	1.4	36
79	In Reply. <i>Obstetrics and Gynecology</i> , 2021, 138, 310-311.	1.2	0
80	Physician attitudes and knowledge on prophylactic salpingectomy in perimenopausal patients. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100824.	0.3	3
81	Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2123616.	2.8	7
82	Adherence to PARP inhibitor therapy among women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 262-268.	0.6	7
83	Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. <i>JAMA Oncology</i> , 2021, 7, 1782.	3.4	21
84	Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 237.e1-237.e24.	0.7	22
85	Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. <i>Gynecologic Oncology</i> , 2021, 162, 599-605.	0.6	5
86	Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy. <i>European Journal of Cancer</i> , 2021, 157, 59-62.	1.3	4
87	Minimally Invasive Surgery for Suspected Early-Stage Ovarian Cancer; A Cost-Effectiveness Study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, , .	1.1	6
88	Trends in the Use of Minimally Invasive Adnexal Surgery in the United States. <i>Obstetrics and Gynecology</i> , 2021, 138, 738-746.	1.2	5
89	In Reply. <i>Obstetrics and Gynecology</i> , 2021, 138, 819-820.	1.2	0
90	Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100887.	0.3	9

#	ARTICLE	IF	CITATIONS
91	Long-term outcomes of vaginal hysterectomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2021, , .	0.6	3
92	Perioperative and persistent opioid utilization following pancreatectomy in the United States. <i>Hpb</i> , 2021, , .	0.1	1
93	The value of volume. <i>Journal of Gynecologic Oncology</i> , 2021, 33, e17.	1.0	0
94	Patterns of cervical cancer screening among Medicaid beneficiaries. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, , .	1.1	1
95	Preeclampsia outcomes at delivery and race. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 3619-3626.	0.7	59
96	Oral Opioid Use during Vaginal Delivery Hospitalizations. <i>American Journal of Perinatology</i> , 2020, 37, 390-397.	0.6	1
97	Postpartum length of stay and risk for readmission among women with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 1086-1094.	0.7	25
98	Effect of regionalization of endometrial cancer care on site of care and patient travel. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 58.e1-58.e10.	0.7	8
99	Fragmentation of postoperative care after surgical management of ovarian cancer at 30 days and 90 days. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 255.e1-255.e20.	0.7	11
100	Opioid Use Disorder during Antepartum and Postpartum Hospitalizations. <i>American Journal of Perinatology</i> , 2020, 37, 1467-1475.	0.6	8
101	Maternal Age and Preeclampsia Outcomes during Delivery Hospitalizations. <i>American Journal of Perinatology</i> , 2020, 37, 044-052.	0.6	16
102	Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1133-1141.e3.	2.4	43
103	Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 484.e1-484.e15.	0.7	16
104	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. <i>Cancer</i> , 2020, 126, 1541-1549.	2.0	12
105	Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. <i>Gynecologic Oncology</i> , 2020, 156, 701-709.	0.6	3
106	Patterns of seizure prophylaxis after oncologic neurosurgery. <i>Journal of Neuro-Oncology</i> , 2020, 146, 171-180.	1.4	21
107	Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies. <i>Journal of Surgical Oncology</i> , 2020, 121, 402-409.	0.8	16
108	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 949-950.	0.7	0

#	ARTICLE	IF	CITATIONS
109	Effect of frailty on postoperative readmissions and cost of care for ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 426-433.	0.6	22
110	Toxicity after adjuvant therapy for stage III uterine cancer. <i>Gynecologic Oncology</i> , 2020, 159, 737-743.	0.6	2
111	Using machine learning to create prognostic systems for endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 159, 744-750.	0.6	23
112	Hospital Safety-Net Burden and Risk for Readmissions and Severe Maternal Morbidity. <i>American Journal of Perinatology</i> , 2020, 38, e359-e366.	0.6	3
113	Minimally invasive radical hysterectomy for early-stage cervical cancer: Volume-outcome relationship in the early experience period. <i>Gynecologic Oncology</i> , 2020, 158, 390-396.	0.6	14
114	Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. <i>Gynecologic Oncology</i> , 2020, 159, 618-622.	0.6	6
115	Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 159, 43-51.	0.6	23
116	COVID-19 outcomes of patients with gynecologic cancer in New York City. <i>Cancer</i> , 2020, 126, 4294-4303.	2.0	51
117	Associations Between Built Environment, Neighborhood Socioeconomic Status, and SARS-CoV-2 Infection Among Pregnant Women in New York City. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 390.	3.8	144
118	Coronavirus Spectrum Infections (COVID-19, MERS, SARS) in Cancer Patients: A Systematic Review of the Literature. <i>Cancer Investigation</i> , 2020, 38, 436-444.	0.6	5
119	Trends in venous thromboembolism prophylaxis in gynecologic surgery for benign and malignant indications. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 935-945.	0.8	3
120	Insurance-Associated Disparities in Opioid Use and Misuse Among Patients Undergoing Gynecologic Surgery for Benign Indications. <i>Obstetrics and Gynecology</i> , 2020, 136, 565-575.	1.2	8
121	The Volume-Outcome Paradigm for Gynecologic Surgery: Clinical and Policy Implications. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 252-265.	0.6	19
122	Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic. <i>European Journal of Cancer</i> , 2020, 139, 173-176.	1.3	9
123	Malignant peritoneal cytology in endometrial cancer: Areas of unmet need for evidence. <i>European Journal of Cancer</i> , 2020, 140, 149-150.	1.3	7
124	Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2017517.	2.8	31
125	Triple stimulation (TriStim) before bilateral oophorectomy in a young woman with ovarian cancer: a case report and review of the literature. <i>Fertility Research and Practice</i> , 2020, 6, 17.	4.1	2
126	The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 309-316.	0.6	16



#	ARTICLE	IF	CITATIONS
127	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. <i>Gynecologic Oncology</i> , 2020, 158, 59-65.	0.6	12
128	Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. <i>Gynecologic Oncology</i> , 2020, 158, 415-423.	0.6	8
129	Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer. <i>JAMA Oncology</i> , 2020, 6, 1019.	3.4	124
130	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. <i>JAMA Oncology</i> , 2020, 6, 1110.	3.4	37
131	Vancomycin during delivery hospitalizations for women with group B streptococcus. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, , 1-9.	0.7	0
132	Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1235-1245.	0.8	6
133	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. <i>Gynecologic Oncology</i> , 2020, 158, 236-243.	0.6	42
134	Receipt of Proton-Pump Inhibitors during Pregnancy and Risk for Preeclampsia. <i>American Journal of Perinatology</i> , 2020, 38, 1519-1525.	0.6	5
135	Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2020, 157, 508-513.	0.6	11
136	A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 157, 329-334.	0.6	4
137	Impact of quality of care on racial disparities in survival for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 396.e1-396.e13.	0.7	30
138	Antibiotics for 3rd and 4th Degree Vaginal Lacerations, Uterine Tamponade, and Manual Placental Extraction. <i>American Journal of Perinatology</i> , 2020, 37, 092-103.	0.6	1
139	Evolving population-based statistics for rare epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2020, 157, 3-11.	0.6	13
140	Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States. <i>Gynecologic Oncology</i> , 2020, 157, 173-180.	0.6	11
141	Fragmentation of postpartum readmissions in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 252.e1-252.e14.	0.7	15
142	Increasing NIH funding for academic departments of obstetrics and gynecology: a call to action. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 79.e1-79.e8.	0.7	18
143	Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer. <i>JAMA Network Open</i> , 2020, 3, e2028612.	2.8	19
144	Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for metastatic ovarian cancer: a national study in the United States. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 863-866.	0.8	4

#	ARTICLE	IF	CITATIONS
145	The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecologic disease in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 721.e1-721.e18.	0.7	28
146	Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. <i>European Journal of Cancer</i> , 2020, 133, 33-46.	1.3	34
147	Postpartum cardiac readmissions among women without a cardiac diagnosis at delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, , 1-7.	0.7	4
148	Prognostic significance of lymphovascular space invasion for stage IA1 and IA2 cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 735-743.	1.2	14
149	A Prediction Model of Microsatellite Status from Histology Images. , 2020, , .		6
150	A High-Throughput Tumor Location System with Deep Learning for Colorectal Cancer Histopathology Image. <i>Lecture Notes in Computer Science</i> , 2020, , 260-269.	1.0	3
151	Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. , 2020, 80, .		0
152	Latino Ethnicity, Immigrant Status, and Preference for End-of-Life Cancer Care. <i>Journal of Palliative Medicine</i> , 2019, 22, 833-837.	0.6	2
153	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 538.	0.7	0
154	Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. <i>Gynecologic Oncology</i> , 2019, 155, 13-20.	0.6	11
155	Use of fertility preservation services in female reproductive-aged cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 328.e1-328.e16.	0.7	21
156	Safety of same-day discharge for minimally invasive hysterectomy for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 239.e1-239.e11.	0.7	15
157	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 505-515.	0.6	11
158	Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , 2019, 18, e294-e299.	1.0	5
159	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 155, 39-50.	0.6	16
160	Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes. <i>Gynecologic Oncology</i> , 2019, 155, 254-261.	0.6	15
161	Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model. <i>PLoS ONE</i> , 2019, 14, e0222828.	1.1	0
162	Decreasing Trends of Secondary Primary Colorectal Cancer among Women with Uterine Cancer: A Population-Based Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 714.	1.0	3

#	ARTICLE	IF	CITATIONS
163	Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. <i>Gynecologic Oncology</i> , 2019, 154, 169-176.	0.6	8
164	Postpartum readmissions among women with opioid use disorder. <i>American Journal of Obstetrics &amp; Gynecology</i> MFM, 2019, 1, 89-98.	1.3	11
165	Financial Toxicity: A Severe But Underrecognized Side Effect for Cancer Patients. <i>Gynecologic Oncology</i> , 2019, 154, 1-2.	0.6	6
166	Regionalization of care for women with ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 394-400.	0.6	6
167	Age-Associated Risk of 90-Day Postoperative Mortality After Cytoreductive Surgery for Advanced Ovarian Cancer. <i>JAMA Surgery</i> , 2019, 154, 669.	2.2	4
168	Trachelectomy for reproductive-aged women with early-stage cervical cancer: minimally invasive surgery versus laparotomy. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 469.e1-469.e13.	0.7	30
169	Patterns of care and outcomes for women with uterine cancer and ovarian metastases. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 365-376.	1.2	4
170	Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 39.e1-39.e14.	0.7	29
171	Substantial Increase in Anesthesia Assistance for Outpatient Colonoscopy and Associated Cost Nationwide. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2489-2496.	2.4	24
172	Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 45-52.	0.6	15
173	FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , 2019, 18, 133-140.	1.0	44
174	Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research. <i>Gynecologic Oncology</i> , 2019, 152, 533-539.	0.6	16
175	Maternal outcomes by race during postpartum readmissions. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 484.e1-484.e10.	0.7	50
176	Risk of unexpected uterine Cancer in women undergoing myomectomy: A population-based study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 238, 188-190.	0.5	1
177	Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 571.e1-571.e8.	0.7	29
178	Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. <i>Gynecologic Oncology</i> , 2019, 153, 368-375.	0.6	39
179	Harnessing Minimally Invasive Surgery to Improve Outcomes in Endometrial Cancer Surgery—The Robots Are Coming. <i>JAMA Surgery</i> , 2019, 154, 539.	2.2	3
180	Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. <i>Obstetrics and Gynecology</i> , 2019, 134, 49-57.	1.2	156

#	ARTICLE	IF	CITATIONS
181	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with <sup>18</sup> F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. International Journal of Gynecological Cancer, 2019, 29, 1351-1354.	1.2	8
182	Use and Misuse of Opioids After Gynecologic Surgical Procedures. Obstetrics and Gynecology, 2019, 134, 250-260.	1.2	46
183	In Reply. Obstetrics and Gynecology, 2019, 133, 826-826.	1.2	0
184	Caring for Patients With Uterine Cancer in Rural and Public Hospitals in New York State. Obstetrics and Gynecology, 2019, 134, 1260-1268.	1.2	2
185	Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer. Obstetrics and Gynecology, 2019, 134, 17-29.	1.2	10
186	Antibiotic Use Without Indication During Delivery Hospitalizations in the United States. Obstetrics and Gynecology, 2019, 134, 718-725.	1.2	8
187	Trends in Use and Effect on Survival of Simple Hysterectomy for Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2019, 134, 1132-1143.	1.2	21
188	Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer. Obstetrics and Gynecology, 2019, 133, 1109-1119.	1.2	9
189	Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer. Lung Cancer, 2019, 129, 8-15.	0.9	5
190	Regional Market Competition and the Use of Immediate Breast Reconstruction After Mastectomy. Annals of Surgical Oncology, 2019, 26, 62-70.	0.7	8
191	Trends in comorbidity, acuity, and maternal risk associated with preeclampsia across obstetric volume settings. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 2680-2687.	0.7	12
192	EP1244...Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. , 2019, , .		0
193	Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model. Gynecologic Oncology, 2018, 149, 241-247.	0.6	4
194	Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions. American Journal of Perinatology, 2018, 35, 898-903.	0.6	14
195	Use of Antihypertensive Medications During Delivery Hospitalizations Complicated by Preeclampsia. Obstetrics and Gynecology, 2018, 131, 441-450.	1.2	32
196	Reply. American Journal of Obstetrics and Gynecology, 2018, 218, 363-364.	0.7	0
197	Racial disparities in young women with endometrial cancer. Gynecologic Oncology, 2018, 148, 527-534.	0.6	34
198	Reply. American Journal of Obstetrics and Gynecology, 2018, 219, 119-120.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma. <i>Cancer Investigation</i> , 2018, 36, 190-198.	0.6	13
200	Impact of hospital volume on racial disparities and outcomes for endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 329-336.	0.6	14
201	Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer. <i>Gynecologic Oncology</i> , 2018, 149, 545-553.	0.6	3
202	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). <i>Gynecologic Oncology</i> , 2018, 149, 232-240.	0.6	8
203	The role of the vaginal microbiome in gynaecological cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 309-315.	1.1	114
204	Risk for postpartum hemorrhage, transfusion, and hemorrhage-related morbidity at low, moderate, and high volume hospitals. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018, 31, 1025-1034.	0.7	27
205	National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 19-25.	1.2	20
206	Rectal balloon use limits vaginal displacement, rectal dose, and rectal toxicity in patients receiving IMRT for postoperative gynecological malignancies. <i>Medical Dosimetry</i> , 2018, 43, 23-29.	0.4	3
207	Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. <i>Gynecologic Oncology</i> , 2018, 148, 19-27.	0.6	15
208	Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. <i>JAMA Surgery</i> , 2018, 153, 344.	2.2	8
209	The modified frailty index and 30-day adverse events in oncologic neurosurgery. <i>Journal of Neuro-Oncology</i> , 2018, 136, 197-206.	1.4	76
210	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 264.	0.7	0
211	Educational Intervention to Improve Code Status Discussion Proficiency Among Obstetrics and Gynecology Residents. <i>American Journal of Hospice and Palliative Medicine</i> , 2018, 35, 724-730.	0.8	5
212	Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms. <i>Neurosurgery</i> , 2018, 83, 263-269.	0.6	14
213	In Reply. <i>Obstetrics and Gynecology</i> , 2018, 132, 519-520.	1.2	1
214	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2710-2717.	0.8	61
215	Effect of Minimum-Volume Standards on Patient Outcomes and Surgical Practice Patterns for Hysterectomy. <i>Obstetrics and Gynecology</i> , 2018, 132, 1229-1237.	1.2	12
216	What Is New in Ovarian Cancer?. <i>Obstetrics and Gynecology</i> , 2018, 132, 1498-1499.	1.2	0

#	ARTICLE	IF	CITATIONS
217	Maternal age and risk for adverse outcomes. American Journal of Obstetrics and Gynecology, 2018, 219, 390.e1-390.e15.	0.7	125
218	Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. American Journal of Obstetrics and Gynecology, 2018, 219, 461.e1-461.e18.	0.7	22
219	Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers. American Journal of Obstetrics and Gynecology, 2018, 219, 463.e1-463.e12.	0.7	14
220	Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. Journal of Gynecologic Oncology, 2018, 29, e91.	1.0	34
221	Trends and Outcomes Associated With Using Long-Acting Opioids During Delivery Hospitalizations. Obstetrics and Gynecology, 2018, 132, 937-947.	1.2	15
222	Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. New England Journal of Medicine, 2018, 379, 1905-1914.	13.9	527
223	Trachelectomy for stage IB1 cervical cancer with tumor size >2 cm: trends and characteristics in the United States. Journal of Gynecologic Oncology, 2018, 29, e85.	1.0	11
224	Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481876592.	1.4	8
225	Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer. Gynecologic Oncology, 2018, 151, 250-256.	0.6	4
226	Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia. JAMA Oncology, 2018, 4, 996.	3.4	2
227	Postpartum hemorrhage outcomes and race. American Journal of Obstetrics and Gynecology, 2018, 219, 185.e1-185.e10.	0.7	85
228	Outcomes of Hysterectomy Performed by Very Low-Volume Surgeons. Obstetrics and Gynecology, 2018, 131, 981-990.	1.2	47
229	Comparative effectiveness of minimally-invasive staging surgery in women with early-stage cervical cancer. Gynecologic Oncology, 2018, 149, 245-246.	0.6	8
230	Characteristics associated with prolonged length of stay after hysterectomy for benign gynecologic conditions. American Journal of Obstetrics and Gynecology, 2018, 219, 89.e1-89.e15.	0.7	20
231	Postpartum venous thromboembolism readmissions in the United States. American Journal of Obstetrics and Gynecology, 2018, 219, 401.e1-401.e14.	0.7	28
232	Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. Gynecologic Oncology, 2018, 150, 501-508.	0.6	11
233	Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. Journal of Gynecologic Oncology, 2018, 29, e69.	1.0	27
234	Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study. Gynecologic Oncology, 2018, 150, 487-493.	0.6	7

#	ARTICLE	IF	CITATIONS
235	Trends in Use and Survival Associated With Fertility-Sparing Trachelectomy for Young Women With Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2018, 131, 1085-1094.	1.2	31
236	Association Between Temporal Changes in Neonatal Mortality and Spontaneous and Clinician-Initiated Deliveries in the United States, 2006-2013. <i>JAMA Pediatrics</i> , 2018, 172, 949.	3.3	22
237	Trends and outcomes of women with synchronous endometrial and ovarian cancer. <i>Oncotarget</i> , 2018, 9, 28757-28771.	0.8	38
238	Utilization of ovarian transposition for fertility preservation among young women with pelvic malignancies who undergo radiotherapy. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 415-417.	0.7	10
239	Changes in Surgical Volume and Outcomes Over Time for Women Undergoing Hysterectomy for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2018, 132, 59-69.	1.2	25
240	Attitudes and Beliefs Regarding the Utility of Robotically Assisted Gynecologic Surgery Among Practicing Gynecologists. <i>Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality</i> , 2017, 39, 211-218.	0.3	7
241	Port Site Metastases: A Survey of the Society of Gynecologic Oncology and Commentary on the Clinical Workup and Management of Port Site Metastases. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 592-598.	0.3	6
242	Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1028-1037.	1.1	45
243	Physicians' Perspectives and Practice Patterns Toward Opportunistic Salpingectomy in High- and Low-Risk Women. <i>Cancer Investigation</i> , 2017, 35, 51-61.	0.6	19
244	Utilization of sentinel lymph node biopsy for uterine cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 594.e1-594.e13.	0.7	25
245	Preventing Endometrial Cancer: Weighing the Evidence. <i>Journal of Clinical Oncology</i> , 2017, 35, 1149-1150.	0.8	0
246	The role of maternal age in twin pregnancy outcomes. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 80.e1-80.e8.	0.7	48
247	Disparities in the management of ectopic pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 49.e1-49.e10.	0.7	38
248	Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies. <i>Cancer Investigation</i> , 2017, 35, 202-214.	0.6	7
249	Trends in operative vaginal delivery, 2005-2013: a population-based study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1365-1372.	1.1	81
250	Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. <i>International Journal of Cancer</i> , 2017, 140, 1396-1404.	2.3	48
251	Case 16-2017 - A 69-Year-Old Woman with Urinary Incontinence. <i>New England Journal of Medicine</i> , 2017, 376, 2066-2073.	13.9	0
252	Patterns of Specialty-Based Referral and Perioperative Outcomes for Women With Endometrial Cancer Undergoing Hysterectomy. <i>Obstetrics and Gynecology</i> , 2017, 130, 81-90.	1.2	36

#	ARTICLE	IF	CITATIONS
253	Utility of radiation therapy for early-stage uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2017, 145, 269-276.	0.6	27
254	The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. <i>Gynecologic Oncology</i> , 2017, 145, 185-191.	0.6	4
255	Laparoscopic Hysterectomy for Endometrial Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1215.	3.8	6
256	Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 59.e1-59.e12.	0.7	8
257	Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. <i>Cancer</i> , 2017, 123, 1333-1344.	2.0	90
258	Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. <i>JAMA Oncology</i> , 2017, 3, 705.	3.4	108
259	Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 558-564.	0.6	37
260	Surgical Antibiotic Prophylaxis and Risk for Postoperative Antibiotic-Resistant Infections. <i>Journal of the American College of Surgeons</i> , 2017, 225, 631-638.e3.	0.2	45
261	Robotic-Assisted Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1545.	3.8	46
262	All-cause mortality in young women with endometrial cancer receiving progesterone therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 669.e1-669.e13.	0.7	27
263	Trends in end-of-life care and health care spending in women with uterine cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 434.e1-434.e10.	0.7	17
264	Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 545-553.	1.2	49
265	Venous Thromboembolism Prophylaxis During Antepartum Admissions and Postpartum Readmissions. <i>Obstetrics and Gynecology</i> , 2017, 130, 270-278.	1.2	10
266	Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 403-410.	1.2	33
267	Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 580.e1-580.e10.	0.7	19
268	Comparative Effectiveness of Cancer Control and Survival after Robot-Assisted versus Open Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 115-121.	0.2	49
269	Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1246-1253.	1.1	23
270	Using publicly reported hospital data to predict obstetric quality. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 1984-1991.	0.7	2



#	ARTICLE	IF	CITATIONS
271	Severe maternal morbidity and comorbid risk in hospitals performing < 1000 deliveries per year. American Journal of Obstetrics and Gynecology, 2017, 216, 179.e1-179.e12.	0.7	27
272	Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 804-813.	1.1	217
273	Laparoscopic staging for apparent stage I epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 2017, 216, 50.e1-50.e12.	0.7	43
274	Inpatient Laparoscopic Hysterectomy in the United States: Trends and Factors Associated With Approach Selection. Journal of Minimally Invasive Gynecology, 2017, 24, 151-158.e1.	0.3	39
275	Cost of Care for the Initial Management of Ovarian Cancer. Obstetrics and Gynecology, 2017, 130, 1269-1275.	1.2	36
276	Practice Patterns, Attitudes, and Barriers to Palliative Care Consultation by Gynecologic Oncologists. Journal of Oncology Practice, 2017, 13, e703-e711.	2.5	37
277	History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. JCO Clinical Cancer Informatics, 2017, 1, 1-12.	1.0	1
278	Placenta Accreta. , 2017, , 456-466.		0
279	Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer. Menopause, 2016, 23, 189-196.	0.8	51
280	Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer. Obstetrics and Gynecology, 2016, 127, 109-118.	1.2	29
281	Electric Power Morcellation in Gynecology. Obstetrics and Gynecology, 2016, 127, 7-9.	1.2	3
282	Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors. Obstetrics and Gynecology, 2016, 127, 449-458.	1.2	3
283	Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer. Obstetrics and Gynecology, 2016, 127, 101-108.	1.2	48
284	Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer. Obstetrics and Gynecology, 2016, 127, 992-1002.	1.2	9
285	Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. Obstetrics and Gynecology, 2016, 127, 985-991.	1.2	22
286	Hospital variation in maternal complications following caesarean delivery in the United States: 2006-2012. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1115-1120.	1.1	9
287	Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynaecological surgery. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 455-461.	1.1	54
288	Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to APO2L/TRAIL-â€Cisplatin combination therapy in cervical cancer. Genes Chromosomes and Cancer, 2016, 55, 177-189.	1.5	18

#	ARTICLE	IF	CITATIONS
289	In through the backdoor: surgical considerations for the morbidly adherent placenta. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 820-820.	1.1	0
290	Abdominal vs Minimally Invasive Hysterectomy“Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2677.	3.8	0
291	Nonadherence to Oral Medications for Chronic Conditions in Breast Cancer Survivors. Journal of Oncology Practice, 2016, 12, e800-e809.	2.5	30
292	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer. Obstetrics and Gynecology, 2016, 128, 761-770.	1.2	56
293	Quality of Postoperative Venous Thromboembolism Prophylaxis in Neuro-oncologic Surgery. Neurosurgery, 2016, 80, 1.	0.6	13
294	Gastroschisis: epidemiology and mode of delivery, 2005“2013. American Journal of Obstetrics and Gynecology, 2016, 215, 348.e1-348.e9.	0.7	54
295	Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study. European Urology, 2016, 70, 195-202.	0.9	85
296	Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2820-2826.	0.8	28
297	Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients. Cancer Investigation, 2016, 34, 189-196.	0.6	9
298	Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. Gynecologic Oncology, 2016, 141, 531-537.	0.6	20
299	Reply. American Journal of Obstetrics and Gynecology, 2016, 215, 134-135.	0.7	0
300	Use of Partial Nephrectomy after Acquisition of a Surgical Robot: A Population Based Study. Urology Practice, 2016, 3, 430-436.	0.2	7
301	Hospital delivery volume, severe obstetrical morbidity, and“failure to rescue. American Journal of Obstetrics and Gynecology, 2016, 215, 795.e1-795.e14.	0.7	47
302	Population-based risk for peripartum hysterectomy during“low- and moderate-risk delivery hospitalizations. American Journal of Obstetrics and Gynecology, 2016, 215, 640.e1-640.e8.	0.7	17
303	National trends in total pelvic exenteration for“gynecologic malignancies. American Journal of Obstetrics and Gynecology, 2016, 215, 395-396.	0.7	8
304	Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation. JAMA - Journal of the American Medical Association, 2016, 316, 877.	3.8	41
305	Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. Cancer Investigation, 2016, 34, 408-414.	0.6	1
306	Do Surgeons or Does Hospital Economics Ultimately Decide Operative Approach?“Reply. JAMA Surgery, 2016, 151, 884.	2.2	1

#	ARTICLE	IF	CITATIONS
307	Utilization and Outcomes of Sentinel Lymph Node Biopsy for Vulvar Cancer. <i>Obstetrics and Gynecology</i> , 2016, 128, 754-760.	1.2	18
308	What Is New in Endometrial Cancer?. <i>Obstetrics and Gynecology</i> , 2016, 128, 904-905.	1.2	4
309	Cytological features of chorionicarcoma in a <sc>P</sc>ap smear: A case report and literature review. <i>Diagnostic Cytopathology</i> , 2016, 44, 324-328.	0.5	3
310	Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998â€“2012. <i>Gynecologic Oncology</i> , 2016, 142, 261-266.	0.6	32
311	Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 3014-3022.	0.8	170
312	Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 548-556.	0.3	46
313	Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1326.	3.4	64
314	Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 387-393.	0.6	52
315	Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis. <i>Cancer Investigation</i> , 2016, 34, 137-147.	0.6	16
316	Natural history and outcome of neuroendocrine carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2016, 141, 247-254.	0.6	72
317	Effect of Regional Hospital Competition and Hospital Financial Status on the Use of Robotic-Assisted Surgery. <i>JAMA Surgery</i> , 2016, 151, 612.	2.2	86
318	Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1087-1096.	0.8	83
319	Applying to subspecialty fellowship: clarifying the confusion and conflicts!. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 243-246.	0.7	14
320	Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 350.e1-350.e10.	0.7	37
321	Underuse of BRCA testing in patients with breast and ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 761-763.	0.7	31
322	Overuse of external beam radiotherapy for stage I endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 75.e1-75.e7.	0.7	6
323	Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 453.	3.4	83
324	Severe placental abruption: clinical definition and associations with maternal complications. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 272.e1-272.e9.	0.7	86

#	ARTICLE	IF	CITATIONS
325	An economic analysis of trial of labor after cesarean delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1030-1035.	0.7	3
326	Population-based assessment of determining predictors for quality of prostate cancer surveillance. <i>Cancer</i> , 2015, 121, 4150-4157.	2.0	24
327	In Reply. <i>Obstetrics and Gynecology</i> , 2015, 126, 898-899.	1.2	2
328	Trends in Relative Survival for Ovarian Cancer From 1975 to 2011. <i>Obstetrics and Gynecology</i> , 2015, 125, 1345-1352.	1.2	99
329	Factors Associated With 30-Day Hospital Readmission After Hysterectomy. <i>Obstetrics and Gynecology</i> , 2015, 125, 461-470.	1.2	30
330	Complications Following Stereotactic Needle Biopsy of Intracranial Tumors. <i>World Neurosurgery</i> , 2015, 84, 1084-1089.	0.7	112
331	Comparative Effectiveness Research in Gynecologic Oncology. <i>Cancer Treatment and Research</i> , 2015, 164, 237-259.	0.2	0
332	Risk stratification and outcomes of women undergoing surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 62-69.	0.6	41
333	Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv251.	3.0	14
334	Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy. <i>JAMA Oncology</i> , 2015, 1, 69.	3.4	65
335	Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 506-512.	0.6	51
336	High versus low-dose rate brachytherapy for cervical cancer. <i>Gynecologic Oncology</i> , 2015, 136, 534-541.	0.6	24
337	Measuring what matters: quality in gynecologic surgery. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 257-258.	0.7	6
338	Reply to A. Kolacevski et al. <i>Journal of Oncology Practice</i> , 2015, 11, 71-71.	2.5	0
339	Trends in Use and Safety of Image-Guided Transthoracic Needle Biopsies in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2015, 11, e351-e359.	2.5	25
340	The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2015, 1, 323.	3.4	26
341	Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2015, 138, 620-626.	0.6	29
342	Relationship Between Surgical Oncologic Outcomes and Publically Reported Hospital Quality and Satisfaction Measures. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	15

#	ARTICLE	IF	CITATIONS
343	Household Net Worth, Racial Disparities, and Hormonal Therapy Adherence Among Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1053-1059.	0.8	102
344	Long-term mortality among women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 421-428.	0.6	54
345	Quality and Outcomes of Treatment of Hypercalcemia of Malignancy. <i>Cancer Investigation</i> , 2015, 33, 331-339.	0.6	34
346	Variation in and Factors Associated With Use of Episiotomy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 197.	3.8	65
347	Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 203-209.	0.6	16
348	Conservative management of morbidly adherent placenta: expert review. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 755-760.	0.7	154
349	Evaluation of Third-Degree and Fourth-Degree Laceration Rates as Quality Indicators. <i>Obstetrics and Gynecology</i> , 2015, 125, 927-937.	1.2	98
350	Center of excellence for placenta accreta. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 561-568.	0.7	388
351	Population-level trends in relative survival for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 670.e1-670.e7.	0.7	39
352	Thromboembolism incidence and prophylaxis during vaginal delivery hospitalizations. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 221.e1-221.e12.	0.7	34
353	Erythropoiesis-Stimulating Agent Use After Changes in Medicare Reimbursement Policies. <i>Journal of Oncology Practice</i> , 2014, 10, 264-269.	2.5	11
354	The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	85
355	Comparative Effectiveness of Robotically Assisted Compared With Laparoscopic Adnexal Surgery for Benign Gynecologic Disease. <i>Obstetrics and Gynecology</i> , 2014, 124, 886-896.	1.2	19
356	Patterns of Use and Predictors of Receipt of Antibiotics in Women Undergoing Cesarean Delivery. <i>Obstetrics and Gynecology</i> , 2014, 124, 338-344.	1.2	14
357	Uterine Pathology in Women Undergoing Minimally Invasive Hysterectomy Using Morcellation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1253.	3.8	132
358	Measure for Measure: The Cost of Improving Quality. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	2
359	An Economic Analysis of Robotically Assisted Hysterectomy. <i>Obstetrics and Gynecology</i> , 2014, 123, 1038-1048.	1.2	83
360	Utility of cell salvage in women undergoing abdominal myomectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 28.e1-28.e8.	0.7	6

#	ARTICLE	IF	CITATIONS
361	Safety and Tolerance of Radical Hysterectomy for Cervical Cancer in the Elderly. <i>Gynecologic Oncology</i> , 2014, 134, 36-41.	0.6	24
362	Nationwide practice patterns for the use of venous thromboembolism prophylaxis among men undergoing radical prostatectomy. <i>World Journal of Urology</i> , 2014, 32, 1313-1321.	1.2	27
363	Surgical management of placenta accreta: to leave or remove the placenta?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 163-170.	1.1	54
364	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 441.	0.7	0
365	Patterns of use of hemostatic agents in patients undergoing major surgery. <i>Journal of Surgical Research</i> , 2014, 186, 458-466.	0.8	54
366	Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. <i>Cancer</i> , 2014, 120, 1246-1254.	2.0	74
367	Failure to rescue after major gynecologic surgery. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 420.e1-420.e8.	0.7	26
368	Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 64-68.	0.6	73
369	Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome. <i>Gynecologic Oncology</i> , 2013, 131, 42-45.	0.6	54
370	Patterns of care for locally advanced vulvar cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 60.e1-60.e5.	0.7	10
371	Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 128, 77-82.	0.6	110
372	Uptake and outcomes of intensity-modulated radiation therapy for uterine cancer. <i>Gynecologic Oncology</i> , 2013, 130, 43-48.	0.6	23
373	Take 'em or leave 'em: Management of the ovaries in young women with endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 131, 287-288.	0.6	15
374	Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 1602-1609.	0.7	53
375	Variation in Ovarian Conservation in Women Undergoing Hysterectomy for Benign Indications. <i>Obstetrics and Gynecology</i> , 2013, 121, 717-726.	1.2	37
376	Robotically Assisted vs Laparoscopic Hysterectomy Among Women With Benign Gynecologic Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 689.	3.8	459
377	Contemporary Clinical Management of Endometrial Cancer. <i>Obstetrics and Gynecology International</i> , 2013, 2013, 1-11.	0.5	39
378	Prognostic Significance of Mucinous Differentiation of Endometrioid Adenocarcinoma of the Endometrium. <i>Cancer Investigation</i> , 2013, 31, 500-504.	0.6	11

#	ARTICLE	IF	CITATIONS
379	Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3592-3599.	0.8	48
380	Underuse of Postcesarean Thromboembolism Prophylaxis. <i>Obstetrics and Gynecology</i> , 2013, 122, 1197-1204.	1.2	35
381	Incidence and Predictors of Bowel Obstruction in Elderly Patients With Stage IV Colon Cancer. <i>JAMA Surgery</i> , 2013, 148, 715.	2.2	101
382	Deviations From Guideline-Based Therapy for Febrile Neutropenia in Cancer Patients and Their Effect on Outcomes. <i>JAMA Internal Medicine</i> , 2013, 173, 559.	2.6	92
383	Use of Guideline-Based Antibiotic Prophylaxis in Women Undergoing Gynecologic Surgery. <i>Obstetrics and Gynecology</i> , 2013, 122, 1145-1153.	1.2	36
384	Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States. <i>Obstetrics and Gynecology</i> , 2013, 122, 233-241.	1.2	566
385	In Reply. <i>Obstetrics and Gynecology</i> , 2013, 122, 906-907.	1.2	0
386	Trends in Hospital Volume and Patterns of Referral for Women With Gynecologic Cancers. <i>Obstetrics and Gynecology</i> , 2013, 121, 1217-1225.	1.2	15
387	NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype. <i>Pathology Discovery</i> , 2013, 1, 4.	0.5	13
388	Reply to C.A. Hudis et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 3150-3150.	0.8	0
389	Reply to S. Sukumar et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2932-2933.	0.8	0
390	Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 806-812.	0.8	27
391	Comparative effectiveness of robotic gynecologic surgery. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 377-379.	0.6	1
392	Failure to Rescue As a Source of Variation in Hospital Mortality for Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3976-3982.	0.8	86
393	Comparative Effectiveness Research in Oncology Methodology: Observational Data. <i>Journal of Clinical Oncology</i> , 2012, 30, 4215-4222.	0.8	129
394	Comparative Effectiveness of Robotic Versus Laparoscopic Hysterectomy for Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 783-791.	0.8	166
395	Use and Benefits of Laparoscopic Hysterectomy for Stage I Endometrial Cancer Among Medicare Beneficiaries. <i>Journal of Oncology Practice</i> , 2012, 8, e89-e99.	2.5	20
396	Acceptance and Compliance With Postpartum Human Papillomavirus Vaccination. <i>Obstetrics and Gynecology</i> , 2012, 120, 771-782.	1.2	24

#	ARTICLE	IF	CITATIONS
397	Effect of Radical Cytoreductive Surgery on Omission and Delay of Chemotherapy for Advanced-Stage Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2012, 120, 871-881.	1.2	89
398	Effect of Surgical Volume on Outcomes for Laparoscopic Hysterectomy for Benign Indications. <i>Obstetrics and Gynecology</i> , 2012, 119, 709-716.	1.2	118
399	Contemporary management of endometrial cancer. <i>Lancet, The</i> , 2012, 379, 1352-1360.	6.3	244
400	Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 11-17.	0.6	126
401	The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 174.e1-174.e7.	0.7	54
402	Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 382.e1-382.e9.	0.7	87
403	Influence of Surgical Volume on Outcome for Laparoscopic Hysterectomy for Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 948-958.	0.7	50
404	Patterns of care and treatment outcomes for elderly women with cervical cancer. <i>Cancer</i> , 2012, 118, 3618-3626.	2.0	95
405	Microinvasive adenocarcinoma of the cervix. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 80.e1-80.e6.	0.7	32
406	Prognostic significance of adenocarcinoma histology in women with cervical cancer. <i>Gynecologic Oncology</i> , 2012, 125, 287-291.	0.6	205
407	Trends in Surgical Mesh Use for Pelvic Organ Prolapse From 2000 to 2010. <i>Obstetrics and Gynecology</i> , 2012, 120, 1105-1115.	1.2	60
408	Risk and Predictors of Malignancy in Women with Endometrial Polyps. <i>Annals of Surgical Oncology</i> , 2011, 18, 3819-3823.	0.7	49
409	Quality of Venous Thromboembolism Prophylaxis in Patients Undergoing Oncologic Surgery. <i>Annals of Surgery</i> , 2011, 253, 1140-1146.	2.1	30
410	Quality of Perioperative Venous Thromboembolism Prophylaxis in Gynecologic Surgery. <i>Obstetrics and Gynecology</i> , 2011, 118, 978-986.	1.2	16
411	Effect of Surgical Volume on Morbidity and Mortality of Abdominal Hysterectomy for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2011, 117, 1051-1059.	1.2	48
412	Transfusion requirements in obstetric patients with placenta accreta. <i>Transfusion</i> , 2011, 51, 2627-2633.	0.8	75
413	Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome. <i>Gynecologic Oncology</i> , 2011, 122, 69-74.	0.6	61
414	Evaluating the significance of location of lymph node metastasis and extranodal disease in women with stage IIIc endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 123, 208-213.	0.6	25



#	ARTICLE	IF	CITATIONS
415	Defining the limits of radical cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 123, 467-473.	0.6	82
416	Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 248.e1-248.e7.	0.7	19
417	Predictors of massive blood loss in women with placenta accreta. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 38.e1-38.e6.	0.7	101
418	Morbidity and mortality of surgery for endometrial cancer in the oldest old. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 66.e1-66.e8.	0.7	30
419	The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 225.e1-225.e7.	0.7	44
420	Natural history and outcome of mucinous carcinoma of the ovary. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 480.e1-480.e8.	0.7	88
421	Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 562.e1-562.e9.	0.7	62
422	Therapeutic role of lymphadenectomy for cervical cancer. <i>Cancer</i> , 2011, 117, 310-317.	2.0	51
423	Foreword. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 197-198.	0.6	1
424	Physician Characteristics and Variability of Erythropoiesis-Stimulating Agent Use Among Medicare Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3408-3418.	0.8	22
425	Management of Endometrial Cancer in Young Women. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 219-225.	0.6	17
426	Scientific Evidence Underlying the American College of Obstetricians and Gynecologists' Practice Bulletins. <i>Obstetrics and Gynecology</i> , 2011, 118, 505-512.	1.2	66
427	Venous Thromboembolism and Use of Prophylaxis Among Women Undergoing Laparoscopic Hysterectomy. <i>Obstetrics and Gynecology</i> , 2011, 117, 1367-1374.	1.2	52
428	Uterine carcinosarcoma. <i>Current Opinion in Oncology</i> , 2011, 23, 531-536.	1.1	60
429	Reply to Racial disparities for uterine corpus tumors. <i>Cancer</i> , 2010, 116, 256-257.	2.0	0
430	Fertility-Conserving Surgery for Young Women With Stage IA1 Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2010, 115, 585-590.	1.2	64
431	Peripartum Hysterectomy. <i>Obstetrics and Gynecology</i> , 2010, 116, 429-434.	1.2	31
432	Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics's Staging System for Uterine Corpus Cancer. <i>Obstetrics and Gynecology</i> , 2010, 116, 1141-1149.	1.2	281

#	ARTICLE	IF	CITATIONS
433	The Effect of Surgeon Volume on Outcomes and Resource Use for Vaginal Hysterectomy. <i>Obstetrics and Gynecology</i> , 2010, 116, 1341-1347.	1.2	84
434	Long-term outcome and natural history of uterine adenosarcomas. <i>Gynecologic Oncology</i> , 2010, 119, 305-308.	0.6	88
435	Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. <i>Cancer</i> , 2010, 116, 2486-2492.	2.0	44
436	Hysterectomy and concurrent oophorectomy for endometrial cancer: which women benefit?. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 49-55.	0.4	0
437	Regionalization of Care for Obstetric Hemorrhage and Its Effect on Maternal Mortality. <i>Obstetrics and Gynecology</i> , 2010, 115, 1194-1200.	1.2	99
438	Morbidity and Mortality of Peripartum Hysterectomy. <i>Obstetrics and Gynecology</i> , 2010, 115, 1187-1193.	1.2	118
439	Stage IIIA Endometrial Carcinoma. <i>Obstetrics and Gynecology</i> , 2009, 114, 100-105.	1.2	18
440	Safety of Ovarian Preservation in Premenopausal Women With Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1214-1219.	0.8	141
441	Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. <i>Gynecologic Oncology</i> , 2009, 114, 75-79.	0.6	44
442	Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. <i>Gynecologic Oncology</i> , 2009, 115, 18-25.	0.6	58
443	Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 419.e1-419.e7.	0.7	48
444	Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 485.e1-485.e9.	0.7	94
445	Surgical Intervention in the Management of Postpartum Hemorrhage. <i>Seminars in Perinatology</i> , 2009, 33, 109-115.	1.1	29
446	Racial disparities for uterine corpus tumors. <i>Cancer</i> , 2009, 115, 1276-1285.	2.0	132
447	Fertility preservation in young women with epithelial ovarian cancer. <i>Cancer</i> , 2009, 115, 4118-4126.	2.0	133
448	Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 983-992.	1.5	61
449	Peritoneal Inclusion Cysts. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 321-334.	0.2	69
450	Improved survival for fallopian tube cancer. <i>Cancer</i> , 2008, 113, 3298-3306.	2.0	65

#	ARTICLE	IF	CITATIONS
451	Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 755-765.	1.5	278
452	The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 536.e1-536.e8.	0.7	78
453	Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. <i>British Journal of Cancer</i> , 2008, 98, 1197-1203.	2.9	83
454	Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: A multi-institutional review. <i>Gynecologic Oncology</i> , 2008, 108, 293-297.	0.6	92
455	Clear cell carcinoma of the cervix: A multi-institutional review in the post-DES era. <i>Gynecologic Oncology</i> , 2008, 109, 335-339.	0.6	69
456	Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2008, 109, 353-358.	0.6	54
457	The utility of preoperative endometrial sampling for the detection of uterine sarcomas. <i>Gynecologic Oncology</i> , 2008, 110, 43-48.	0.6	128
458	Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers. <i>Obstetrics and Gynecology</i> , 2008, 112, 64-70.	1.2	104
459	Current treatment strategies for endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1149-1157.	1.1	12
460	Natural history of established low grade cervical intraepithelial (CIN 1) lesions. <i>Anticancer Research</i> , 2008, 28, 1763-6.	0.5	67
461	Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. <i>Cancer</i> , 2007, 110, 1281-1286.	2.0	176
462	Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, 280-284.	0.6	1
463	The impact of cervical cancer on quality of life. The components and means for management. <i>Gynecologic Oncology</i> , 2007, 107, 572-577.	0.6	78
464	Bevacizumab therapy in patients with recurrent uterine neoplasms. <i>Anticancer Research</i> , 2007, 27, 3525-8.	0.5	35
465	Human Papillomavirus Triage for Young Women With Atypical Squamous Cells of Undetermined Significance. <i>Obstetrics and Gynecology</i> , 2006, 107, 822-829.	1.2	18
466	Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. <i>Gynecologic Oncology</i> , 2006, 102, 86-91.	0.6	18
467	Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2006, 103, 489-493.	0.6	85
468	Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2006, 102, 552-562.	0.6	41

#	ARTICLE	IF	CITATIONS
469	Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. <i>Cancer</i> , 2006, 107, 83-89.	2.0	130
470	Cervical Dysplasia in Adolescents. <i>Obstetrics and Gynecology</i> , 2005, 106, 115-120.	1.2	53
471	Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1379-1381.	0.7	37
472	Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. <i>Gynecologic Oncology</i> , 2005, 98, 84-91.	0.6	21
473	Cervical sarcomas: An analysis of incidence and outcome. <i>Gynecologic Oncology</i> , 2005, 99, 348-351.	0.6	58
474	Cervical carcinoma in the elderly. <i>Cancer</i> , 2005, 103, 85-91.	2.0	83
475	Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. <i>Cancer</i> , 2005, 104, 2484-2491.	2.0	168
476	Relationship of ovarian neoplasms and body mass index. <i>Journal of reproductive medicine, The</i> , 2005, 50, 595-602.	0.2	5
477	Synchronous ovarian metastases at the time of laparotomy for colon cancer. <i>Gynecologic Oncology</i> , 2004, 92, 851-855.	0.6	46
478	Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. <i>Gynecologic Oncology</i> , 2004, 94, 436-441.	0.6	26
479	A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?. <i>Gynecologic Oncology</i> , 2004, 95, 70-76.	0.6	45
480	Morbidity of cytoreductive surgery in the elderly. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 1398-1400.	0.7	65
481	Is hypotonic dysfunctional labor associated with hypophosphatemia?. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 1447-1449.	0.7	0
482	Atypical Squamous Cells of Undetermined Significance in Girls and Women. <i>Obstetrics and Gynecology</i> , 2004, 103, 632-638.	1.2	9
483	Prenatally diagnosed human caudal appendage: a case report. <i>Journal of reproductive medicine, The</i> , 2004, 49, 566-8.	0.2	9
484	Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2003, 91, 134-138.	0.6	16
485	Acute abdominal pain with a calcified pelvic mass. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2003, 16, 237-241.	0.3	3
486	Treatment of High-Risk Gestational Trophoblastic Tumors. <i>Clinical Obstetrics and Gynecology</i> , 2003, 46, 593-606.	0.6	16

#	ARTICLE	IF	CITATIONS
487	Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy. <i>Obstetrics and Gynecology</i> , 2002, 100, 1141-1144.	1.2	11
488	Human papillomavirus: emerging trends in detection and management. <i>Current Women's Health Reports</i> , 2002, 2, 259-65.	0.2	9
489	Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. <i>Journal of reproductive medicine, The</i> , 2002, 47, 933-5.	0.2	2
490	Coordinate Regulation of Prostaglandin Metabolism for Induction of Parturition in Mice. , 0, .		11
491	Association between immigrant status and advanced cancer patients' location and quality of death. <i>Cancer</i> , 0, , .	2.0	0
492	Efficacy of a password-protected, pill-dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery. <i>Cancer</i> , 0, , .	2.0	0